Paroxetine versus Venlafaxine and Escitalopram in Korean Patients with Major Depressive Disorder: A Randomized, Rater-blinded, Six-week Study

키워드

참고문헌 (62)

1. Alonso J, "Prevalence of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project", Acta Psychiatr Scand Suppl, (420), pp.21~27 (2004)
2. Alegria M, "Considering context, place and culture: the National Latino and Asian American Study", Int J Methods Psychiatr Res, 13, pp.208~220 (2004)
3. Takeuchi DT, "Lifetime and twelve-month prevalence rates of major depressive episodes and dysthymia among Chinese Americans in Los Angeles", Am J Psychiatry, 155, pp.1407~1414 (1998)
4. Ferrari AJ, "Global variation in the prevalence and incidence of major depressive disorder : a systematic review of the epidemiological literature", Psychol Med, 43, pp.471~481 (2013)
5. Weissman MM, "Cross-national epidemiology of major depression and bipolar disorder", JAMA, 276, pp.293~299 (1996)
6. Yeung A, "Mood disorders in Asians", Asian J Psychiatr, 7, pp.71~73 (2014)
7. Iwata N, "Race", ethnicity and depressive symptoms:a cross-cultural, Soc Sci Med, pp.2002, 55[DOI]
8. Cho MJ, "Use of the Center for Epidemiologic Studies Depression(CES-D)scale in Korea", J Nerv Ment Dis, 186, pp.304~310 (1998)
9. Lin KM, "Biological differences in depression and anxiety across races and ethnic groups", J Clin Psychiatry, 62(Suppl 13), pp.13~19 (2001)
10. Darmansjah I, "Dose-response variation among different populations", Clin Pharmacol Ther, 52, pp.449~452 (1992)
11. 우영섭, "Dose Trends of Aripiprazole from 2004 to 2014 in Psychiatric Inpatients in Korea", Clinical Psychopharmacology and Neuroscience, 15(2), pp.177~180 (2017), 대한정신약물학회
12. Mundo E, "The role of serotonin transporter protein gene in antidepressantinduced mania in bipolar disorder : preliminary findings", Arch Gen Psychiatry, 58, pp.539~544 (2001)
13. Zanardi R, "Factors affecting fluvoxamine antidepressant activity : influence of pindolol and 5-HTTLPR in delusional and nondelusional depression", Biol Psychiatry, 50, pp.323~330 (2001)
14. Perlis RH, "Serotonin transporter polymorphisms and adverse effects with fluoxetine treatment", Biol Psychiatry, 54, pp.879~883 (2003)
15. Kim K, "Differences in drug pharmacokinetics between East Asians and Caucasians and the role of genetic polymorphisms", J Clin Pharmacol, 44, pp.1083~1105 (2004)
16. Palmatier MA, "Global variation in the frequencies of functionally different catechol-O-methyltransferase alleles", Biol Psychiatry, 46, pp.557~567 (1999)
17. Zhang M, "Major depressive disorder treatment guidelines in China", J Clin Psychiatry, 71(Suppl E1), pp.e06~ (2010)
18. Higuchi T, "Major depressive disorder treatment guidelines in Japan", J Clin Psychiatry, 71(Suppl E1), pp.e05~ (2010)
19. Seok Seo J, "The Korean medication algorithm for depressive disorder : second revision", J Affect Disord, 167, pp.312~321 (2014)
20. 원은수, "Evidence-Based, Pharmacological Treatment Guideline for Depression in Korea, Revised Edition", Journal of Korean Medical Science, 29(4), pp.468~484 (2014), 대한의학회
21. Treuer T, "Use of antidepressants in the treatment of depression in Asia: guidelines, clinical evidence, and experience revisited", Asia Pac Psychiatry, 5, pp.219~230 (2013)
22. Suzuki A, "A three-factor model of the MADRS in major depressive disorder", Depress Anxiety, 21, pp.95~97 (2005)
23. Sheehan DV, "Handbook of psychiatric measures", pp.113~115 (2000), American Psychiatric Association
24. Lingjaerde O, "The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients", Acta Psychiatr Scand Suppl, 334, pp.1~100 (1987)
25. Hayasaka Y, "Dose equivalents of antidepressants : Evidence-based recommendations from randomized controlled trials", J Affect Disord, 180, pp.179~184 (2015)
26. Cipriani A, "Comparative efficacy and acceptability of 12 new-generation antidepressants : a multipletreatments meta-analysis", Lancet, 373, pp.746~758 (2009)
27. Purgato M, "Paroxetine versus other anti-depressive agents for depression", Cochrane Database Syst Rev, (4), pp.CD006531~ (2014)
28. Hong Ng C, "A comparative study of sertraline dosages, plasma concentrations, efficacy and adverse reactions in Chinese versus Caucasian patients", Int Clin Psychopharmacol, 21, pp.87~92 (2006)
29. Chi MH, "Comparison of antidepressant efficacy-related SNPs among Taiwanese and four populations in the HapMap database", J Formos Med Assoc, 110, pp.478~482 (2011)
30. Preissner SC, "Polymorphic cytochrome P450enzymes (CYPs) and their role in personalized therapy", PLoS One, 8, pp.e82562~ (2013)
31. Sanchez C, "A comparative review of escitalopram, paroxetine, and sertraline: Are they all alike?", Int Clin Psychopharmacol, 29, pp.185~196 (2014)
32. Rao N, "The clinical pharmacokinetics of escitalopram", Clin Pharmacokinet, 46, pp.281~290 (2007)
33. Jornil J, "Identification of cytochrome P450 isoforms involved in the metabolism of paroxetine and estimation of their importance for human paroxetine metabolism using a population-based simulator", Drug Metab Dispos, 38, pp.376~385 (2010)
34. Magalhães P, "Venlafaxine pharmacokinetics focused on drug metabolism and potential biomarkers", Drug Metabol Drug Interact, 29, pp.129~141 (2014)
35. Spina E, "Clinical applications of CYP genotyping in psychiatry", J Neural Transm(Vienna), 122, pp.5~28 (2015)
36. Chen PY, "Biological variations in depression and anxiety between East and West", CNS Neurosci Ther, 15, pp.283~294 (2009)
37. Kirchheiner J, "Pharmacogenetics of antidepressants and antipsychotics : the contribution of allelic variations to the phenotype of drug response", Mol Psychiatry, 9, pp.442~473 (2004)
38. Lee MS, "Role of genetic polymorphisms related to neurotransmitters and cytochrome P-450 enzymes in response to antidepressants", Drugs Today(Barc), 43, pp.569~581 (2007)
39. Lobello KW, "Cytochrome P450 2D6 phenotype predicts antidepressant efficacy of venlafaxine : a secondary analysis of 4 studies in major depressive disorder", J Clin Psychiatry, 71, pp.1482~1487 (2010)
40. Mulder H, "The association between cytochrome P450 2D6 genotype and prescription patterns of antipsychotic and antidepressant drugs in hospitalized psychiatric patients : a retrospective follow-up study", J Clin Psychopharmacol, 25, pp.188~191 (2005)
41. D'Empaire I, "Antidepressant treatment and altered CYP2D6 activity: are pharmacokinetic variations clinically relevant?", J Psychiatr Pract, 17, pp.330~339 (2011)
42. Kalow W, "Ethnic difference in drug metabolism : debrisoquine 4-hydroxylation in Caucasians and Orientals", Can J Physiol Pharmacol, 58, pp.1142~1144 (1980)
43. Bousman CA, "Escitalopram efficacy in depression : a crossethnicity examination of the serotonin transporter promoter polymorphism", J Clin Psychopharmacol, 34, pp.645~648 (2014)
44. Kang RH, "Association study of the serotonin transporter promoter polymorphism and mirtazapine antidepressant response in major depressive disorder", Prog Neuropsychopharmacol Biol Psychiatry, 31, pp.1317~1321 (2007)
45. Kim DK, "Serotonin transporter gene polymorphism and antidepressant response", Neuroreport, 11, pp.215~219 (2000)
46. Yoshida K, "Influence of the serotonin transporter gene-linked polymorphic region on the antidepressant response to fluvoxamine in Japanese depressed patients", Prog Neuropsychopharmacol Biol Psychiatry, 26, pp.383~386 (2002)
47. Yoshimura R, "Rapid response to paroxetine is associated with plasma paroxetine levels at 4but not 8 weeks of treatment, and is independent of serotonin transporter promoter polymorphism in Japanese depressed patients", Hum Psychopharmacol, 24, pp.489~494 (2009)
48. Chen H, "Self-attention as a mediator of cultural influences on depression", Int J Soc Psychiatry, 49, pp.192~203 (2003)
49. Waza K, "Comparison of symptoms in Japanese and American depressed primary care patients", Fam Pract, 16, pp.528~533 (1999)
50. Parker G, "Do the Chinese somatize depression? A cross-cultural study", Soc Psychiatry Psychiatr Epidemiol, 36, pp.287~293 (2001)
51. Georg Hsu LK, "Stigma of depression is more severe in Chinese Americans than Caucasian Americans", Psychiatry, 71, pp.210~218 (2008)
52. Trivedi MH, "Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D : implications for clinical practice", Am J Psychiatry, 163, pp.28~40 (2006)
53. Iosifescu DV, "The impact of medical comorbidity on acute treatment in major depressive disorder", Am J Psychiatry, 160, pp.2122~2127 (2003)
54. Papakostas GI, "Somatic symptoms in treatmentresistant depression", Psychiatry Res, 118, pp.39~45 (2003)
55. Klengel T, "Somatization in major depression--clinical features and genetic associations", Acta Psychiatr Scand, 124, pp.317~328 (2011)
56. Serretti A, "Serotonin transporter gene influences the time course of improvement of"core"depressive and somatic anxiety symptoms during treatment with SSRIs for recurrent mood disorders", Psychiatry Res, 149, pp.185~193 (2007)
57. Taylor SE, "Early family environment, current adversity, the serotonin transporter promoter polymorphism, and depressive symptomatology", Biol Psychiatry, 60, pp.671~676 (2006)
58. Nock MK, "Suicide among soldiers : a review of psychosocial risk and protective factors", Psychiatry, 76, pp.97~125 (2013)
59. Hansen RA, "Controlling for drug dose in systematic review and meta-analysis : a case study of the effect of antidepressant dose", Med Decis Making, 29, pp.91~103 (2009)
60. Warden D, "Income and attrition in the treatment of depression : a STAR*D report", Depress Anxiety, 26, pp.622~633 (2009)
61. Warden D, "Predictors of attrition during one year of depression treatment : a roadmap to personalized intervention", J Psychiatr Pract, 15, pp.113~124 (2009)
62. Turvey CL, "Cultural differences in depression-related stigma in late-life: a comparison between the USA, Russia, and South Korea", Int Psychogeriatr, 24, pp.1642~1647 (2012)

관련 논문AI추천